CR20140505A - (r) -nifuratel y sintesis de (r) - nifuratel - Google Patents
(r) -nifuratel y sintesis de (r) - nifuratelInfo
- Publication number
- CR20140505A CR20140505A CR20140505A CR20140505A CR20140505A CR 20140505 A CR20140505 A CR 20140505A CR 20140505 A CR20140505 A CR 20140505A CR 20140505 A CR20140505 A CR 20140505A CR 20140505 A CR20140505 A CR 20140505A
- Authority
- CR
- Costa Rica
- Prior art keywords
- nifuratel
- synthesis
- disclosed
- bactericide
- surprisingly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C241/02—Preparation of hydrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Se divulgan (R)-nifuratel junto con su uso como bactericida y agente bacteriostático, así como las composiciones farmacéuticas que lo contienen; sorpresivamente se ha descubierto que (R)-nifuratel posee un mejor perfil antimicrobiano que cualquiera de los dos, el racemato de nifuratel o el (S)-nifuratel. Se divulga asimismo un nuevo procedimiento para la síntesis de los dos, el (R)-nifuratel y el (S)-nifuratel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20120167640 EP2662371A1 (en) | 2012-05-11 | 2012-05-11 | (R)-Nifuratel and synthesis of (R) and (S)-Nifuratel |
PCT/EP2013/055078 WO2013167295A1 (en) | 2012-05-11 | 2013-03-13 | (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20140505A true CR20140505A (es) | 2015-02-06 |
Family
ID=47846051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20140505A CR20140505A (es) | 2012-05-11 | 2014-11-03 | (r) -nifuratel y sintesis de (r) - nifuratel |
Country Status (27)
Country | Link |
---|---|
US (2) | US9284306B2 (es) |
EP (2) | EP2662371A1 (es) |
JP (1) | JP2015515998A (es) |
KR (1) | KR20150008871A (es) |
CN (1) | CN104379580A (es) |
AU (1) | AU2013258385A1 (es) |
BR (1) | BR112014027953A2 (es) |
CA (1) | CA2869827A1 (es) |
CL (1) | CL2014002951A1 (es) |
CO (1) | CO7131368A2 (es) |
CR (1) | CR20140505A (es) |
DO (1) | DOP2014000252A (es) |
EA (1) | EA201492081A1 (es) |
EC (1) | ECSP14026432A (es) |
GE (2) | GEP201606595B (es) |
HK (1) | HK1202539A1 (es) |
IL (1) | IL235429A0 (es) |
IN (1) | IN2014DN09256A (es) |
MA (1) | MA20150279A1 (es) |
MX (1) | MX2014013759A (es) |
NZ (1) | NZ700752A (es) |
PE (1) | PE20150167A1 (es) |
PH (2) | PH12014502500A1 (es) |
SG (2) | SG10201608485XA (es) |
TN (1) | TN2014000430A1 (es) |
WO (1) | WO2013167295A1 (es) |
ZA (1) | ZA201407596B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108254453A (zh) * | 2016-12-28 | 2018-07-06 | 苏州电器科学研究院股份有限公司 | 一种有效测定塑料制品中邻苯二甲酸酯含量的检测方法 |
IL273387B2 (en) | 2017-09-20 | 2023-10-01 | Ph Pharma Co Ltd | Thylanstatin analogs |
CN108760950B (zh) * | 2018-04-25 | 2022-07-15 | 国检测试控股集团京诚检测有限公司 | 一种测定硝基呋喃代谢物的方法 |
CN111892557B (zh) * | 2019-05-05 | 2022-11-08 | 河北圣泰材料股份有限公司 | 哌嗪类成膜离子液体的合成方法 |
CN110672765B (zh) * | 2019-10-11 | 2022-03-18 | 温州海鹤药业有限公司 | 一种定量检测硝呋太尔中顺式异构体杂质的方法 |
CN112457304B (zh) * | 2020-12-07 | 2022-03-11 | 中国药科大学 | 一种硝呋太尔的制备方法 |
CN113828243B (zh) * | 2021-09-14 | 2022-06-28 | 南京南大药业有限责任公司 | 一种硝呋太尔制霉菌素栓制造方法及设备 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL120945C (es) | 1962-08-01 | |||
CN100506820C (zh) | 2006-03-16 | 2009-07-01 | 韩志强 | (s)-硝呋太尔,其制备方法和应用 |
CN100516063C (zh) * | 2006-03-16 | 2009-07-22 | 韩志强 | 硝呋太尔的生产方法 |
CN101434584A (zh) * | 2007-11-15 | 2009-05-20 | 中山大学 | 具有抗菌活性的手性噁唑烷酮类化合物 |
EP2243482A1 (en) * | 2009-04-20 | 2010-10-27 | Polichem SA | Use of nifuratel to treat infections caused by atopobium species |
-
2012
- 2012-05-11 EP EP20120167640 patent/EP2662371A1/en not_active Withdrawn
-
2013
- 2013-03-13 GE GEAP201313660A patent/GEP201606595B/en unknown
- 2013-03-13 JP JP2015510685A patent/JP2015515998A/ja active Pending
- 2013-03-13 EA EA201492081A patent/EA201492081A1/ru unknown
- 2013-03-13 SG SG10201608485XA patent/SG10201608485XA/en unknown
- 2013-03-13 IN IN9256DEN2014 patent/IN2014DN09256A/en unknown
- 2013-03-13 US US14/400,071 patent/US9284306B2/en not_active Expired - Fee Related
- 2013-03-13 BR BR112014027953A patent/BR112014027953A2/pt not_active IP Right Cessation
- 2013-03-13 NZ NZ700752A patent/NZ700752A/en not_active IP Right Cessation
- 2013-03-13 SG SG11201406447SA patent/SG11201406447SA/en unknown
- 2013-03-13 MA MA37496A patent/MA20150279A1/fr unknown
- 2013-03-13 CN CN201380022803.0A patent/CN104379580A/zh active Pending
- 2013-03-13 GE GEAP201313967A patent/GEP201706626B/en unknown
- 2013-03-13 WO PCT/EP2013/055078 patent/WO2013167295A1/en active Application Filing
- 2013-03-13 CA CA 2869827 patent/CA2869827A1/en not_active Abandoned
- 2013-03-13 PE PE2014001944A patent/PE20150167A1/es not_active Application Discontinuation
- 2013-03-13 AU AU2013258385A patent/AU2013258385A1/en not_active Abandoned
- 2013-03-13 KR KR20147031517A patent/KR20150008871A/ko not_active Application Discontinuation
- 2013-03-13 MX MX2014013759A patent/MX2014013759A/es unknown
- 2013-03-13 EP EP13708840.7A patent/EP2847189A1/en not_active Withdrawn
-
2014
- 2014-10-16 TN TN2014000430A patent/TN2014000430A1/fr unknown
- 2014-10-20 ZA ZA2014/07596A patent/ZA201407596B/en unknown
- 2014-10-30 CL CL2014002951A patent/CL2014002951A1/es unknown
- 2014-10-30 IL IL235429A patent/IL235429A0/en unknown
- 2014-11-03 CR CR20140505A patent/CR20140505A/es unknown
- 2014-11-07 DO DO2014000252A patent/DOP2014000252A/es unknown
- 2014-11-10 PH PH12014502500A patent/PH12014502500A1/en unknown
- 2014-11-11 EC ECIEPI201426432A patent/ECSP14026432A/es unknown
- 2014-11-11 CO CO14248543A patent/CO7131368A2/es unknown
-
2015
- 2015-01-28 US US14/607,464 patent/US9067927B2/en not_active Expired - Fee Related
- 2015-03-26 HK HK15103057.7A patent/HK1202539A1/xx unknown
- 2015-09-24 PH PH12015502241A patent/PH12015502241A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20140505A (es) | (r) -nifuratel y sintesis de (r) - nifuratel | |
SV2017005514A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
DOP2016000253A (es) | Nuevos compuestos | |
CL2012001971A1 (es) | Compuestos derivados de 1-piperazinil-3-piridin-carboxilato, como bloqueadores de los canales de sodio dependientes de voltaje; composicion farmaceutica; y su uso para el tratamiento de enfermedades respiratorias o del tracto respiratorio tal como asma, epoc, tos, silicosis, entre otras. | |
GT201500069A (es) | Piridinonas bicìclicas novedosas | |
SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
UY34111A (es) | Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
UY36651A (es) | Compuestos antiestrogénicos | |
DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
GT201500143A (es) | Composiciones que comprenden vortioxetina y donepezilo campo tecnico | |
UY34166A (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. | |
CR20150417A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
BR112015023878A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
MX359955B (es) | Formulación de aroma y fragancia (iii). | |
MX2015004312A (es) | Formulacion de aroma y fragancia (i). | |
UY33862A (es) | Nuevos compuestos de benzamida, composiciones agroquímicas que los contienen, procesos de preparación y usos? | |
CR20140526A (es) | Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis | |
MX360017B (es) | Formulación de aroma y fragancia (iv). |